United States· US:46708-576_c9aa6022-4a1b-4fd5-a7ba-04158d9b5a05
Pramipexole Dihydrochloride
A pramipexole product containing pramipexole dihydrochloride, registered in United States by Alembic Pharmaceuticals Limited. The same ATC class is registered in 18 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Pramipexole is registered in 18 of 19 countries.
Countries holding a registration under ATC N04BC05 (pramipexole), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 10 of them publish a price we can compare per daily dose
Pramipexole · ATC N04BC05
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of pramipexole costs, country by country.
Normalised to the WHO defined daily dose (2.5 mg), the median price runs from $0.28 in United States to $5.68 in Switzerland — a ×20 gap.
- United States: $0.28 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Pramipexole · price per daily dose (2.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$5.68
- IT Italy$2.62
- FR France$1.32
- US United States$0.28 (acquisition cost)
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- PRAMIPEXOLE DIHYDROCHLORIDE
- Manufacturer
- Alembic Pharmaceuticals Limited
- Country
- United States (US)
- ATC code
- N04BC05
- ATC class
- Pramipexole
- Defined daily dose
- 2.5 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1146708-576-30
- ndc11467085763030 TABLET, EXTENDED RELEASE in 1 BOTTLE (46708-576-30)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
197 interactions on record for pramipexole.
Graded by severity as the source publishes them — 51 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pramipexole · interactions on record
197 records
- 51 moderate
- 3 minor
- 138 info
Most severe, free to view
- CimetidineA02BA01moderate
- MetoclopramideA03FA01moderate
- ThiethylperazinA04AB03moderate
- DiphenhydraminA04AB05moderate
5 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pramipexole in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandPramipexol-Mepha ER 1.5 mg, DepotabsMepha Pharma AG
- United KingdomMirapexin 0.088mg tabletsBoehringer Ingelheim Ltd
- CzechiaCALMOLANG.L. Pharma GmbH, Lannach
- FinlandDaquiranBoehringer Ingelheim Pharma GmbH & Co. KG
- SwedenCalmolan 0,26 mg DepottablettG.L. Pharma GmbH
- SpainMIRAPEXIN 0,088 mg COMPRIMIDOSBoehringer Ingelheim International Gmbh
- BelgiumMirapexin 0.088 mgBoehringer Ingelheim International
- NetherlandsGlepark 0,088 mg tablettenGlenmark Arzneimittel GmbH
Authorised across Europe · EMA
The same active substance is authorised in 28 EEA countries. Names it is sold under:
- Austria · Calmolan, Calmolan Retard
- Belgium · Pramipexol, Pramipexol Eg
- Bulgaria · Parson, Peximyr 0,18 Mg
- Cyprus · Medopexol, Rapexole
- Czechia · Calmolan, Glepark
- Germany · Glepark, Pexapral
- Denmark · Glepark, Mariprax
- Spain · Pramipexol Aurovitas, Pramipexol Aurovitas Spain
- Finland · Pramipexol, Pramipexol Stada
- France · Pramipexole Arrow Lab, Pramipexole Biogaran
- United Kingdom (Northern Ireland) · Pipexus, Pramipexole Glenmark Pharmaceuticals Europe
- Greece · Glepark, Mariprax
- Croatia · Pramipeksol Pliva
- Hungary · Calmolan, Erimexol
- Ireland · Miramel
- Iceland · Mirapexin, Oprymea
- Italy · Pramiperal, Pramipexolo Aurobindo
- Liechtenstein · Mirapexin, Pramipexole Teva
- Lithuania · Pramipexole Orion
- Luxembourg · Pramipexol Eg, Pramipexole Eg
- Latvia · Pramipexole Elvim, Pramipexole Orion
- Malta · Pramipexole Aurobindo
- Netherlands · Glepark, Pramipexol Aurobindo
- Norway · Mirapexin, Oprymea
- Portugal · Pramipexol Aurobindo, Pramipexol Azevedos
- Romania · Pramipexol Arena, Pramipexol Stada
- Sweden · Calmolan, Derinik
- Slovakia · Glepark, Pramipexol Stada
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ec9bfa1e-74af-4f2f-a590-1801382e162d GET /v1/drugs/ec9bfa1e-74af-4f2f-a590-1801382e162d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "1.5",
"substance": "PRAMIPEXOLE DIHYDROCHLORIDE",
"productndc": "46708-576",
"dosage_form": "TABLET, EXTENDED RELEASE",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "ANDA204518",
"marketing_category": "ANDA"
}See everything about pramipexole.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.